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1. Introduction 
Nanomedicine, the medical application of nanotechnology, is poised to make a major impact 
on the diagnosis and treatment of many diseases. It is a relatively new branch of science that 
involves harnessing the unique properties of particles that are nanometers in scale 
(nanoparticles) for both diagnostic and therapeutic applications. Nanoparticles (NPs) can be 
engineered with precise sizes, shapes, compositions and surface chemistries for specific 
applications. In particular, nanoparticles are uniquely suited for the treatment of cancers 
and cardiovascular diseases. NPs can be engineered with surface targeting ligands against 
cancer markers or atherosclerosis markers, which in turn allow the specific detection of as 
well as specific drug delivery to these diseases. In the case of cancer, nanoparticles also 
preferentially accumulate in tumors due to the enhanced permeability and retention (EPR) 
effect (Noguchi et al. 1998).  Although nanomedicine is a relatively new field, it has been 
quickly translated into clinical medicine and has led to a number of clinically-approved 
agents. Today, there are more than twenty nanoparticle therapeutics in clinical use. 
Furthermore, a 2006 global survey conducted by the European Science and Technology 
Observatory (Duconge et al.) revealed that more than 150 companies are developing 
nanoscale therapeutics, highlighting the high enthusiasm for nanoparticle-based 
therapeutics (Wagner et al. 2006).  
While nanomedicine has many facets, radioisotopes have been an integral component. 
Radioisotopes have been extensively utilized in the development of nanoparticle-based 
therapeutics. Radiolabeling has been the predominant method for the accurate assessment 
of biodistribution, circulation half-life, and pharmacokinetics of nanoparticles. In addition, 
there has been great interest in developing nanoparticles with dual diagnostic and 
therapeutic functionalities (theranostics) and radioisotopes have been a natural fit for the 
diagnostic component. Lastly, therapeutic radioisotopes can also be delivered by 
nanoparticles, especially for the treatment of cancer. In this chapter, we will review the 
various applications of radioisotopes in nanomedicine in detail. We also plan to discuss the 
methods of incorporating radioisotopes into nanoparticles as well as preclinical and clinical 
data on radioisotope containing nanoparticle diagnostics and therapeutics. 
2. Nanoparticle platforms  
Nanomedicine is a fairly new and rapidly developing branch of science. First described in 
1965, liposomes are one of the first structures manufactured on a nanometer scale to be 
applied in medicine (Bangham 1993). Over the past 15 years, there has been a rapid growth 
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of interest in NPs probably due in large part to the inherent flexibility in the construction 
and design of the particles. 
Liposomal agents were the first NP platform to make it into the clinic and have since been 
joined by a number of other nanoparticle classes. These various platforms include polymer-
therapeutic conjugates, polymeric micelles, dendrimers, nanoshells, nucleic acid-based 
nanoparticles and carbon nanotubes (Wang et al. 2008). Liposomes are spherical lipid 
containers enclosing an aqueous space. Depending on design, they can range in size from tens 
of nanometers up to micrometers in size (Torchilin 2005). The outer sphere is composed of a 
phospholipid bilayer which acts a hydrophobic shell around the aqueous core. This allows for 
entrapment of hydrophilic compounds within the liposomes. Conversely, hydrophobic drugs 
can be incorporated into the lipid bilayer itself. The outside surface of the bilayer is exposed 
and can therefore act as a point of interaction between a liposome and a biosystem. The 
liposomal surface can be functionalized with targeting agents such as antibodies, protective 
polymers such as polyethylene glycol to prevent opsonization by the immune system, or 
diagnostic labels such as radioisotopes (Torchilin 2005).  
Most of the next generation nanoparticle therapeutics are biodegradable polymer 
nanoparticles, which have been extensively investigated as therapeutic carriers (Kim et al. 
2005). Polymeric nanoparticles are generally formulated by the self-assembly of block-
copolymers consisting of two or more polymer chains with different hydrophobicity. These 
copolymers spontaneously assemble into a core-shell structure in an aqueous environment 
through the hydrophobic hydrophilic interactions. Specifically, the hydrophobic blocks form 
the core to minimize their exposure to aqueous surroundings while the hydrophilic blocks 
form the shell to stabilize the core (Farokhzad et al. 2004). This results in a structure ideally 
suited for drug delivery. The hydrophobic core is capable of carrying therapeutics with high 
loading capacity (5-25 % weight). The hydrophilic shell not only provides a steric protection 
for the micelle, but also provides functional groups for further particle surface 
modifications. Polymeric nanoparticles have been formulated to encapsulate either 
hydrophilic or hydrophobic small drug molecules, and macromolecules such as proteins 
and nucleic acids (Gu et al. 2008).  
Fullerene carriers are another well-studied nanoparticle platform which includes both 
spherical carbon “buckyballs” and carbon nanotubes (CNTs). Both have potential as carriers 
for radioisotopes, in particular because of their ability to shield the reactive radioisotopes 
from the biosystem while at the same time allowing for modification of the outside of the 
nanotube for targeted therapy (Mackeyev et al. 2005). CNTs have cylindrical architecture 
with an extremely high length-to-diameter ratio. Until recently this system had not been 
successfully tested in vivo. Researchers at Oxford carried out the first experiments in a 
mouse model with I-125-filled, single-walled carbon nanotubes. Though iodine is rapidly 
taken up by thyroid tissue, researchers were able to completely redirect the CNTs to lung. 
This suggests that the iodine was entirely shielded from the circulation. This particular 
platform also set a record for radiation ionizing dose per gram of carrier at 800% (70% 
represents a reasonable prior in vivo benchmark).  By surface functionalizing this platform, 
researchers hope to show versatility of targeting which may allow for extremely high doses 
of radiation to be delivered very selectively (Hong et al. 2010; Strano 2010).   
Other platforms of nanoparticle delivery have been extensively studied including 
dendrimers, metal nanoparticles, nanoemulsions and nucleic acid based nanoparticles 
(Wang et al. 2008). The interest in these other nanoparticle platforms is growing and several 
dendrimer-based antiviral therapies are currently in clinical trials. Investigators have also 
www.intechopen.com
 
Radioisotopes and Nanomedicine 49 
developed metallic nanoshells used for controlled release of chemotherapy. Each of these 
platforms has unique properties and holds promise for almost every branch of medicine. 
Much of this work continues in the preclinical stages with a few drugs now making it to 
clinical trials.   By improving the stealth properties and optimizing the payload capacities of 
these various nanomolecules, there is great hope and high expectations that this branch of 
science can continue to make wide-ranging contributions to medicine.  
3. Common isotopes for nanomedicine and incorporation strategies 
Selection of an isotope for imaging or therapy depends on a number of parameters.  For 
imaging, radioisotopes should have decay properties conducive to detection. In positron 
emission tomography (PET) imaging, the energy is invariably 511 keV due to positron 
decay; however, for single-photon emission computed tomography (SPECT) imaging ideal 
energy is 100 keV to 200 keV(Phillips et al. 2009). The photons must be of sufficient energy 
to penetrate the body while still allowing for adequate collimation for spatial localization. 
The half-life of the isotope is also important to consider, particularly in relation to the 
duration of expected nanoparticle circulation. For instance, fluorine-18 as a component of 
fluorodeoxyglucose-positron emission tomography (FDG-PET) is most commonly used in 
clinical practice. With a half-life of 110 minutes, this allows for adequate time to allow 
uptake of the FDG while it retains enough activity to be clinically detected after getting a 
patient to the scanner, but not so much as to require long periods of detection time or as to 
retain substantial in vivo activity for more than a day.  The same principles guide selection of 
laboratory isotope half-life, particularly when selecting PET-agents which have a wider 
range of half-life. Commercially available PET agents range in half-life from 2 minutes up to 
4 days (Table 1) (Delbeke & Martin 2001; 2004). Naturally, nanoparticles with longer 
expected circulation time will require PET agents with longer half-life while those with 
relatively short circulation times should be tracked using isotopes with shorter half-life to 
improve photon yield over time. This selection process is complicated by variation in 
stability amongst different isotopes-nanoparticle combinations (Phillips et al. 2009). It is 
important to consider both in vitro and in vivo stability because unstable labeling can lead to 
incorrect measurements of biodistribution via isotope loss.  Many methods have been 
described for labeling nanoparticles, most commonly liposomal platforms. The method of 
labeling can also greatly affect stability of the conjugate (Phillips et al. 2009). 
To be useful in the laboratory setting, radiolabeled nanoparticles ideally need to meet 
certain criteria. Important factors include ease and efficiency of preparation as well as 
stability of isotope-nanoparticle conjugate without in vitro or in vivo release of the 
radioisotope. Steady advancements in this area have led to increasing stability of isotope 
labeled liposomes, some of which are being translated into the clinic for diagnostic 
molecular imaging (Hahn et al. 2011).  
Due to the relatively short half-life of the commonly used radioisotopes, nanoparticles 
should be labeled shortly before being used. This is referred to as “after loading” or 
“remote-labeling.”  Though not ideal, a very simple strategy for radiolabeling liposomes is 
to incubate the premanufactured liposomes with a lipophilic isotope (Phillips et al. 2009). 
This leads to emulsion of the isotope into the lipid bilayer; however, while this method is 
fairly simplistic, it results in a very unstable conjugation. Several more effective “after 
loading” techniques have been described that yield more stable isotope-liposome 
conjugations (Harrington et al. 2001).  
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Selected radioisotopes used for nanoparticle detection and imaging
Radionuclide Detection Method T½ Photon Energy (Bult et al.) 
Gallium-67 SPECT 3.3 d 93, 185, 300
Indium-111 SPECT 2.8 d 171, 245
Iodine-123 SPECT 13.2 h 159
Rhenium-186 SPECT 3.72 d 137, 132
Technetium-99m SPECT 6.01 h 141
Iodine-125 SPECT 59 d 36 
Carbon-11 PET 20 min 511
Copper-64 PET 12.7 h 511
Copper-62 PET 3.5 h 511
Fluorine-18 PET 109 min 511
Gallium-68 PET 68 min 511
Iodine-124 PET 4.2 d 511
Oxygen-15 PET 2 min 511
Zirconium-89 PET 78 h 511
Hydrogen-3 Scintillation 12.3 y (ǃ=18.5 keV)
Carbon-14 Scintillation 5730 y (ǃ=156 keV)
Table 1. Common radioisotopes for nanoparticle imaging. All are generated by cyclotron 
with the exception of Tc-99m which comes from Molybdenum-99/Tc-99m generators, 
resulting in a substantially lower relative cost because it is easier to obtain. 
Radiolabeling via surface chelation was first described 30 years ago and is still used today. 
Hnatowich et al. first described chelation of both Ga-67 and Tc-99m via diethylenetriamine 
pentacetic acid (DTPA), a metal chelator (Hnatowich et al. 1981). More recently, Torchilin et 
al. published a method of radiolabeling liposomes with In-111 using 
phosphatidylethanolamine (PE) conjugated to DTPA (DTPA-PE). For Tc-99m a separate 
method has been developed by Laverman et al. (Laverman et al. 1999). A technetium 
chelator, N-hydroxysuccinimidyl hydrazine nicotinate hydrochloride (HYNIC), is 
conjugated to a free amino group of the liposome and incorporated via surface chelation to 
premanufactured liposomes. The liposomes are then incubated with Tc-99m prior to the 
start of the study (Laverman et al. 1999). External conjugation suffers from the potential for 
in vivo interactions between the labels and other biomolecules as well as surface crowding 
that could affect interactions with other functional groups on the liposome.  
To help overcome this problem, other methods of “after loading” have been developed, 
specifically internal chelation. This approach utilizes liposomes that encapsulate a reactive 
species. The radiolabel is conjugated to a lipophilic chelator that can pass through the lipid 
bilayer (Harrington et al. 2001). Upon reaching the inside of the liposome, the complex 
interacts with the internal molecule, effectively entrapping it within the liposome. 
Numerous investigators have developed methods of radiolabeling based on this principle of 
internal chelation. Examples include In-111-oxine incubated with liposomes encapsulating 
DTPA leading to anchoring of the isotope (Harrington et al. 2001); Tc-99m-
hexamethylpropyleneamine oxime incubated with liposomes encapsulating glutathione 
causing conversion to a hydrophilic form of the Tc-99m conjugate(Phillips et al. 1992); 
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Rhenium-186-N,N-bis(2-mercaptoethyl)-N’,N’-diethylethylenediamine reacting with 
encapsulated cysteine (Bao et al. 2003); and halogenated I-123 combining with intra-
liposomal arginine (Mougin-Degraef et al. 2006). Each of the reactions secures the label 
within the core of the nanoparticle which in general results in greater stability of the 
radiolabeled liposome.  
Because of the wide range of methods used for incorporation of therapeutic radionuclides, 
discussion of these strategies is reserved for the specific examples cited later in the chapter 
(Table 2). 
 
Selected radioisotopes under study for nanoparticle radiotherapy 
Radionuclide 
Nanoparticle 
Platform 
Notable 
Decays 
T½ Reference 
Iodine-131 Synthetic polymer ┛, ┚ 8 d (Klutz et al. 2009) 
Holmium-166 Acetylacetone ┛, ┚ 27 h (Bult et al. 2010) 
Lutetium-177 
Liposome, 
fullerene cage 
┚ 161 h (Helbok et al. 2010) 
Rhenium-186 Liposome ┛, ┚ 89 h (French et al. 2010) 
Rhenium-188 
Liposome, 
iron oxide 
┛, ┚ 17 h (Liang et al. 2007) 
Yttirium-90 
Lipid-polymer 
hybrid 
┚ 64 h (Wang et al. 2010) 
Indium-111 
Biotinylated 
streptavidin 
Auger, ┛ 67 h (Natarajan et al. 2008b) 
Iodine-125 
Biotinylated 
streptavidin 
Auger, ┛ 60 d (Liu et al. 2010) 
Actinium-225 Mineral lattice ┙ 10 d (Woodward et al. 2011) 
Gold-198 Dendrimer ┚ 2.7 d (Khan et al. 2008) 
Table 2. Radioisotopes that have been tested in preclinical models. Radioisotopes that decay 
by both electron and photon emission have potential as theranostic agents. 
4. Radioisotope applications in nanomedicine 
Radionanoparticles have three core applications: drug development, imaging and therapy. 
We will discuss these applications and how they are being combined to provide unique 
avenues for the treatment of disease.  
4.1 Radioisotopes for nanoparticle biodistribution and drug development 
Nowhere have radioisotopes been more influential in nanomedicine than in their use for 
preclinical drug development. By successfully incorporating radioisotopes into the structure 
of a nanoparticle in such a way as to minimally influence external structure, nanoparticles 
can be tracked by radioactive decay (Ting et al. 2010). A variety of methods using an array 
of different isotopes have been developed for this purpose (Phillips et al. 2009). Gamma 
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photon imaging, in the form of positron emission tomography and single photon emission 
computed tomography (Racker & Spector), are the predominant methods of tracking in vivo 
particle biodistribution. Particle distribution is tracked via detection of emitted photons 
from isotope decay. In the case of PET, annihilation photons of 511 keV (generated when a 
positron and shell electron collide) emitted at 180 degrees from one another are detected and 
used to localize the particle (Chen & Conti 2010). SPECT uses emission of a single photon 
combined with collimation to allow photons of predictable trajectories to be recorded; thus, 
the particle decay can be localized within the body. In clinical practice, both methods have 
issues with spatial resolution; however, the level of localization is adequate for determining 
in vivo biodistribution.  
The choice of radioisotope depends on a number of characteristics including the type of NP 
platform, ease of preparation and stability of the isotope-NP conjugate as well as 
availability, expense and decay characteristics of the radioisotope (Phillips et al. 2009).    For 
instance, Tc-99m is readily available in most hospitals, and accounts for about 80% of the 
nuclear medicine tests worldwide (IAEA 2011); thus, it is commonly used for nanoparticle 
labeling. Carbon-14 was one of the first elements used to track the fate of nanoparticles by 
measuring urinary excretion of the isotope (Bazile et al. 1992). Tritium also has a long 
history of being used for tracking the fate of nanoparticles (Kukowska-Latallo et al. 2005; 
Takahama et al. 2009). These two radioisotopes are popular due to their long half-lives and 
ease of incorporation. Both radioisotopes are beta emitters and thus require dissection for in 
vivo quantification (Shokeen et al. 2008). Over the past two decades, SPECT and PET 
detection have emerged as facile ways of tracking internal biodistribution without the need 
for dissection to quantify uptake. Copper-64 is a commonly used agent for PET imaging that 
can be incorporated into a variety of nanoparticles for in vivo tracking (Fukukawa et al. 2008; 
Pressly et al. 2007; Rossin et al. 2005; Schipper et al. 2007; Xie et al. 2010a; Xie et al. 2010b). 
It’s conjugation to nanoparticles is much easier than that of the more common clinical 
radioisotope fluorine-18 and is the primary reason it is used over this more clinically useful 
isotope. Indium-111 and Technitium-99m both have long track records for use in drug 
development as SPECT imaging agents (DeNardo et al. 2007; Elbayoumi et al. 2007; 
Kobayashi et al. 1999; Lin et al. 2009; Natarajan et al. 2008a; Natarajan et al. 2008b; Phillips et 
al. 2009). Similarly, several iodine radioisotopes (I-123, I-124, I-125) have been used for 
SPECT (Chrastina & Schnitzer 2010; Geze et al. 2007; Gratton et al. 2007; Kennel et al. 2008; 
Kumar et al. 2010; Malik et al. 2000; Medina et al. 2011). Other PET agents such as Gallium-
68 are in use as well (Helbok et al. 2010; Phillips et al. 2009).    Many of these radioisotopes 
are being used in molecular imaging agents. 
4.2 Molecular imaging with nanoparticles 
Nanoparticles have received a great deal of attention in the past decade in large part due to 
their potential for use in molecular imaging. As targeting specificity improves, methods of 
detection should simultaneously improve, leading to earlier detection of conditions such as 
heart disease and cancer. While radiolabeled liposomes have been studied for some time, only 
recently have researchers developed multifaceted imaging agents with the potential for human 
use. Active work in this area involves PET, SPECT, MRI and quantum dots. Molecular 
imaging has evolved a great deal over the past decade, and one of the most intriguing aspects 
of nanoparticle molecular imaging is the potential for designing combination particles for use 
as multifaceted imaging agents. To date, most combinations of the various imaging modalities 
have been combined at some level with varying levels of success. 
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Single modality carriers 
There is good rationale for functionalizing nanoparticles with PET or SPECT agents for 
imaging. While glucose analog agents such as FDG show tumor uptake through the 
Warburg effect (Gatenby & Gillies 2004), specificity may be increased via the enhanced 
permeability and retention (EPR) effect (Noguchi et al. 1998). Additionally, nanocarriers 
may be functionalized with targeting ligands to further improve specificity for their target 
(Wang et al. 2008).  
Despite its widespread use in the clinic for imaging, fluorine-18 is difficult to efficiently 
functionalize to targeted nanoparticles for this purpose. Due to its long half-life relative to 
other isotopes (carbon-11, nitrogen-13, oxygen-15), F-19 is a F-19 is a better candidate 
candidate for PET nanoparticles as there is sufficient time to functionalize the NP with 
radioisotope prior to administration.  In 2008, Matson et al. were the first to demonstrate 
efficient synthesis of F-19 labeled micelle nanoparticles (Matson & Grubbs 2008). This may 
pave the way for better imaging agents using NPs. 
Elements such as copper-64 are much easier to functionalize to NP because of their longer 
half-life (12.7 h), and thus to this point it has been used more frequently than fluorine. 
Chakrabarti et al. designed a peptide nucleic acid probe radiolabeled with copper-64 to 
target mutated KRAS mRNA. KRAS is mutated at a very high level in pancreatic cancer and 
mutated KRAS mRNA is expressed at a high level in these tumors suggesting it may be a 
good target for early detection or targeted therapy. To achieve cellular uptake, peptide 
nanoparticles were combined with an IGF1-analog peptide to allow for internalization by 
IGF1 receptor-mediated endocytosis. IGF1 receptor is commonly upregulated in human 
cancers, including pancreatic cancer. Authors designed a series of radiohybridization probes 
linked with copper-64 to target various single nucleotide polymorphisms in KRAS mRNA. 
The probe had good selectivity for KRAS-mutated in mice engrafted with AsPC1, a 
pancreatic cancer cell line (Chakrabarti et al. 2007). Similarly, Petersen et al. designed 
copper-64 labeled liposomes for PET imaging in a mouse model (Petersen et al. 2011). 
Authors have described the targeting of tumor neovasculature with both SPECT and PET 
nanoparticles. Hu et al. designed an indium-111 labeled perfluorocarbon nanoparticle targeted 
to ǂvǃ3, an integrin characteristically overexpressed in tumor neovasculature. In a rabbit 
model, the authors demonstrated a high sensitivity, low-resolution signal for tumor 
vasculature (Hu et al. 2007). Perfluorocarbons NP may also be used for MRI (Schmieder et al. 
2005) allowing for a dual modality probe in the future that would increase this resolution 
while maintaining sensitivity. Ruggiero et al. imaged tumor vasculature using zirconium-89 
labeled carbon nanotubes to target the monomeric vascular-endothelial cadherin epitobe that 
is frequently overexpressed in tumor vasculature (Ruggiero et al. 2010). The versatile carbon 
nanotube may prove to be both an efficient imaging and therapeutic nanoparticle platform. 
These dual modality (theranostic) particles will be discussed in detail later. More recently, Sun 
et al. published imaging data on the clinically available nanoparticle albumin-bound paclitaxel 
(Abraxane, Celegene). To judge early response to therapy, researchers attached either the PET 
agent 18F-FPPRGD2, a novel radiopharmaceutical shown to target ǂvǃ3(Mittra et al. 2010), or 
standard 18F-FDG to Abraxane. The authors concluded that the novel agent was more 
sensitive than 18F-FDG for early detection of tumor response, likely due to down-regulation of 
ǂvǃ3 in tumor endothelial cells when responding to Abraxane therapy (Sun et al. 2011). 
The utility of nanoparticle SPECT versus PET agents was directly compared by Cheng et al. 
Tc-99m and F-18 were each conjugated individually to an anti-HER-2 nanoparticle, and the 
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agents were tested in a mouse model with HER-2-positive xenografts. Despite the better 
resolution of Tc-99m, F-18 was 15 times more sensitive for in vivo tumor detection. 
Unfortunately, covalent attachment of F-18 is a much more difficult process than chelation 
of Tc-99m to the nanoparticle platform (Cheng et al. 2010); however, due to its much higher 
sensitivity, at this time, PET appears to be the choice modality for clinical applications.  
Dual modality carriers 
One of the exciting features of nanoparticle platforms is their versatility. Researchers are 
actively investigating almost every permutation of the various imaging modalities in 
combination with nanoparticle carriers. The list of potential modalities includes PET, 
SPECT, MRI and quantum dots (QD). While a full description of investigations into 
nanoparticle MRI and QD is beyond the scope of this chapter, each will be described as they 
pertain to multifaceted imaging nanoparticles involving PET and SPECT.  
QD are nano-sized semiconductors with unique optical properties specific to the size and 
possibly the shape of the semiconductor crystal. In medical imaging, quantum dots are 
being studied as fluorophores, particles that absorb and emit energy of characteristic wave 
lengths. QD have been used in vitro for applications such as cell labeling and fluorescence in 
situ hybridization (Jiang et al. 2007; Wu et al. 2003). To date, in vivo use has been mostly 
limited to non-specific applications such as qualitative imaging of lymph nodes and 
vasculature in animal models (Hikage et al. 2010).  Progress for medical applications has 
been hindered by technical challenges such as toxicity and characterization of the in vivo 
fluorescence signal (Aillon et al. 2009; Zhang & Badea 2011). 
Despite these challenges, several researchers have described multifaceted nanoparticles for 
imaging with either PET or SPECT in combination with QD. Cai et al. designed cadmium 
QD functionalized with RGD peptide, a ǂvǃ3 antagonist, and labeled with copper-64. This 
allowed for simultaneous near-infrared fluorescence (NIRF) and PET imaging. The probe 
was tested in a murine glioblastoma model and correlation between the in vivo PET signal 
and ex vivo QD fluorescence was excellent. On histologic examination, the nanoparticle 
exhibited specificity for tumor neovasculature. This study allowed for accurate 
determination of the probe biodistribution. A major advantage of this probe may be the gain 
in sensitivity with PET. This allows for the use of lower levels of cadmium QD to achieve 
accurate imaging. In the future, this will be of key importance for quantum dots to reduce 
the potential for toxicity from metals used in the semiconductors (Cai et al. 2007).  
Similarly, Duconge et al. reported the first F-18-labeled QD using a PEG-phospholipid QD 
micelles. Pegylation allowed for prolonged circulation (T1/2 of 2 h) and reduced RES uptake.  
Researchers were able to study the biodistribution both by whole body PET and by QD 
fluorescence using in vivo fibered confocal fluorescence microscopy. The authors conclude 
that this system effectively utilizes two molecular imaging modalities simultaneously: PET 
for whole body imaging and fluorescence imaging for subcellular localization of tumor cells  
(Duconge et al. 2008). SPECT-QD combinations have also been described (Liang et al. 2010). 
While one can envision clinical applications of these probes for invasive procedures, they 
still suffer from the inability to assess the fluorescence signal in deep tissue without direct 
surgical intervention.  
This is not the case for dual MRI/PET probes which both allow for non-invasive imaging in 
vivo. While several researchers have looked at MRI/SPECT (Lijowski et al. 2009; Park et al. 
2011; Torres Martin de Rosales et al. 2011; Zielhuis et al. 2006), the much improved 
sensitivity of positron emitting probes makes PET a much more enticing option for dual 
www.intechopen.com
 
Radioisotopes and Nanomedicine 55 
modality imaging. MRI allows for excellent spatial resolution that PET is lacking while PET 
improves upon the suboptimal sensitivity of MRI for functional imaging. The combination is 
appealing because of this complimentary nature (Cheon & Lee 2008).  
Several investigators have designed iron oxide nanoparticles with copper-64 for dual 
modality imaging (Glaus et al. 2010; Jarrett et al. 2008; Patel et al. 2011). Jarrett et al. had 
previously demonstrated the use of an MRI compatible PET scanner to obtain simultaneous 
images using separate imaging probes (Catana et al. 2006; Judenhofer et al. 2007; Wu et al. 
2009). Preclinical results are awaited using these untargeted nanoparticles in a model system 
for dual modality imaging. Several authors have developed and tested a similar iron oxide 
nanoparticles labeled with copper-64 and functionalized the carriers with integrin–binding 
ǂvǃ3 RGD peptide (Lee et al. 2008; Yang et al. 2011). Researchers have tested the particles in 
vivo in a mouse model; however, the MRI characterization was performed without copper-
64 due to limitations of the MR scanner (Lee et al. 2008). Despite this, imaging results 
between the two modalities were comparable.  
Trimodality imaging agents and beyond 
With clinical application of multifunctional imaging nanoparticles on the horizon, 
researchers have continued to push the limits of what is achievable with a single 
nanoparticle agent. Several authors have described trimodality imaging nanoparticles used 
for PET, MR and fluorescence imaging (Devaraj et al. 2009; Ko et al. 2011; Nahrendorf et al. 
2008; Zhou et al. 2011), and at least one group has published on the synthesis of a 
tetramodality particle that allows for bioluminescence and fluorescence imaging as well as 
PET and MRI using a cobalt-ferrite nanoparticle (Hwang do et al. 2009). 
4.3 Therapeutic radionanoparticles 
While much of the early work on therapeutic nanoparticles focused on drug delivery, there is 
increasing interest in targeting diseases, specifically cancer, via therapeutic doses of internal 
radiation. Improvements in functionality and streamlining of manufacturing are leading to 
multidimensional particles capable of delivering multiple therapies via a single carrier.   
Internal radiation therapy already has a track record as a useful modality in the clinic. 
Iodine-131 therapy has long been a standard ablative therapy for both non-malignant 
thyroid diseases as well as thyroid cancer. In the past 5 years several radioimmunotherapies 
(Davies et al.) using monoclonal antibodies have been approved for clinical use. 
Radiolabeled anti-CD-20-antibody therapies Y-90-ibritumomab tiuxetan (Zevalin, Spectrum 
Pharmaceuticals) and I-131-tositumomab (Bexxar, GlaxoSmithKline) have shown promising 
results in clinical trials for the treatment of relapsed/refractory non-Hodgkin’s lymphoma 
(Davies et al. 2004; Vose et al. 2005; Vose et al. 2000) and are now being tested as part of 
initial treatment in clinical trials (Fisher 2005; NA 2006; Press et al. 2006). A limitation of RIT 
is that only one radioisotope can be attached per antibody (Jestin et al. 2007). Yttrium-90-
microspheres, an agent in clinical use for ablation of hepatic malignancies, overcome this 
first problem but due to their size must be injected directly into the hepatic arterial supply to 
result in meaningful tumor ablation without substantial toxicity (Cosimelli et al. 2010; 
Hendlisz et al. 2010; Kennedy & Salem 2010). Other transarterial embolic agents tagged with 
Lu-177, Rh-188 and Ho-166 have been developed (Chakraborty et al. 2008; Hamoudeh et al. 
2007; Kim et al. 2006), but all range in size from 300 nm up to 60 μm. Nanoparticles may be 
able to overcome both the size and payload problems and provide a systemic route to 
selectively deliver a larger radioisotope and/or drug payload.  
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Radioisotopes with various decay properties are being utilized for therapeutic 
nanoparticles. With penetration ranges of 1-10 mm and energies 0.1-2.2 MeV, beta-emitting 
isotopes such as those in clinical use for RIT may be ideal candidates for nanoparticle 
radiation. The range of beta particles allows the so-called “cross-fire” effect as it is greater 
than several cell diameters. However, the decay property should match the goal of therapy 
(Sofou 2008). For instance, particles that decay through alpha emission may be attractive 
alternatives for targeting intravascular micrometastases due to high linear energy transfer. 
These particles are limited by a penetration range of 50-100 μm making them less well suited 
for bulky tumor deposits. Auger electrons, with a path length of less than 10 nm such as 
those produced by Indium-111, have been suggested as potential therapeutic agents for 
small volume disease if carriers can be internalized in high enough numbers to result in 
meaning radiation dose deposition to the tumor cell DNA. One theoretical appeal of auger-
mediated therapy is that the short path length also suggests a low potential for toxicity 
(Tavares & Tavares 2010). 
Many of the studies involving therapeutic radionanoparticles have been theoretical and 
qualitative in nature. Such studies have looked at modeling of radio-loaded nanoparticles 
with various decay properties with mixed theoretical results. Bouchat et al. modeled Y-90 
labeled antibody biodistribution by Monte Carlo code and showed that RIT would not result 
in tumor doses sufficient to treat solid tumors such as lung cancer (biological effective dose 
< 60 Gy). Using a similar modeling system, they showed that radioactive nanoparticles with 
~100 Y-90 atoms per nanoparticle can substantially increase the biologic effective dose 
deposited to a solid tumor (Bouchat et al. 2010). Additionally, radioisotopes that are usually 
insoluble in body fluids can be encapsulated within nanoparticles, allowing them to be 
sequestered until delivery at the target (Khan et al. 2008). Hrycushko et al. have modeled 
liposomes tagged with both beta emitters Re-186 and Re-188 for the post-surgical treatment 
of breast cancer, showing this to be a potential method of delivering focal radiation to the 
locations at highest risk for harboring residual cancer cells while sparing normal tissue 
(Hrycushko et al. 2011a; Hrycushko et al. 2011b).  
Preclinical development of therapeutic radionanoparticles has been primarily directed at the 
treatment of cancer often involving concurrent beta decay (for therapy) and gamma decay 
(for imaging). Rapid advances in the ability to functionalize nanoparticle platforms for 
diagnostic and therapeutic purposes have led investigators to develop dual purpose 
particles, a field now known as theranostics. Many of the therapeutic nanoparticles fall into 
this category owing to multiple decay pathways of the incorporated radioisotopes, most 
often involving concurrent both beta decay for therapy and gamma decay for imaging.  
While some authors consider dual imaging nanoparticles to be theranostic agents (Ma et al. 
2006), this section will deal only with those agents that have been considered for therapeutic 
use. To date, the study of therapeutic radionanoparticles has involved a wide range of 
nanoparticle platforms combined with an even vaster array of radioisotopes. The section is 
organized by type of radiation decay (beta, alpha, and auger) as each has its own unique 
applications and shortcomings when used for internal radiation therapy (Sofou 2008).  
Beta decay radionanoparticles 
Radioisotopes decaying through beta emission are perhaps the best studied agents for 
nanoparticle radiotherapy. With a path length of 1-10 mm, beta particles traverse multiple 
cells while interacting, leading to a “cross fire” effect. Therefore, tagged-NPs do not require 
www.intechopen.com
 
Radioisotopes and Nanomedicine 57 
cellular internalization to provide effective cell kill.  The particle range may also allow for 
potential cell kill in areas of tumor lacking good vascular access.  
Significant research has gone into gold nanoparticles for imaging and enhancement of 
external beam irradiation, but until recently, little successful work had been published using 
beta-emitting gold nanoparticles for internal radiation therapy. Though first described for 
this purpose several decades ago, nanoparticle technology was not as robust at that time, 
and efforts to deliver internal radiation with gold were discontinued (Hainfeld et al. 1990). 
Recently, Khan et al. demonstrated the antitumor effect of dendrimer nanoparticles carrying 
therapeutic loads of Au-198. Researchers generated the radioactive composite nanodevice 
(CND) by simultaneous neutron activation and radiation polymerization of dendrimers 
tagged with Au-197. Neutron capture formed Au-198 which could then decay by beta 
emission. In a melanoma model, tumors of mice injected with the Au-198 CND decreased in 
size by 45% compared to the untagged CND with no observed toxicity (Khan et al. 2008). 
Chanda et al. described a similar Au-198 NP with good therapeutic efficacy and low toxicity 
in a murine prostate cancer model (Chanda et al. 2010). 
Several other platforms have been developed for delivery of internal beta irradiation. 
Schultz et al. described a fullerene cage nanoparticle tagged with Lu-177 for targeting Il-13, 
an interleukin characteristically overexpressed on glioblastoma cells (Shultz et al. 2010). 
Diener et al. devised a similar fullerene system incorporating Pb-212, a beta emitter with an 
alpha-emitting daughter radionuclide, Bi-212 (Diener et al. 2007). Reactive ionic 
radioisotopes such as Lu and Pb must be shielded from the microenvironment to prevent 
interaction. Fullerene cages are attractive nanoparticles for this purpose because the ions are 
completely enclosed within the platform. Ho-166 is another appealing candidate 
radioisotope due to its concurrent gamma and beta decays as well as its high attenuation 
coefficient and paramagnetic properties. This combination suggests it to have wide-ranging 
potential as a true theranostic agent. With this in mind, Bult et al. successfully developed an 
acetylacetone nanoparticle labeled with Ho-166 (Bult et al. 2010); though, the particle has yet 
to be tested as a therapeutic agent in an animal model.  
Alpha decay radionanoparticles 
While beta-emitters have received the bulk of the attention for radionanoparticles, alpha 
emitters possess unique qualities that make them viable therapy candidates. One such 
radioisotope is Ac-225, which has received attention as an in vivo radiation generator. Ac-225 
decays through two chains of short-lived radioisotopes, yielding 4 alpha particles and 
ending in stable Bi-209. A challenge of these generators is to prevent leakage of the daughter 
radionuclides during circulation, and nanoparticles are being studied as a way to retain 
decay chain products for delivery at the target site. Two groups have developed 
nanoparticles capable of daughter particle retention to a limited extent. Sofou et al. designed 
a multivesicular liposomal carrier of Ac-225 to enhance retention of daughter radionuclides. 
Though retention was not as high as hoped, when the particles were targeted to an ovarian 
cell line in vitro using immunolabeling with anti-HER2/neu, they were internalized at an 
impressive rate (Sofou et al. 2007).  More recently, Woodward et al.developed a lanthum 
phosphate nanoparticle (LaPO4 NP) for Ac-225 encapsulation. The particles were conjugated 
with antibodies to lung endothelium. This system showed better retention of the daughter 
nuclides in the LaPO4 NP and excellent dose deposition in mouse lung tissue (Woodward et 
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al. 2011). Effective targeting and daughter retention suggest this model may have 
therapeutic potential in humans.  
Auger decay radionanoparticles 
Due to their short range, auger electrons rely on high selective cellular uptake and 
incorporation in cellular DNA to result in meaning tumoricidal effect. To date, In-111, I-123 
and I-125 have been studied as potential agents for this purpose (Chow et al. 2008; Liu et al. 
2010; Liu et al. 2009; Mamede et al. 2003; Reske et al. 2007).  
Combined modality particles for cancer treatment 
Radiation is a major treatment modality for cancer along with surgery and chemotherapy. 
Over the past 20 years, a large body of evidence has shown that chemotherapy can 
synergistically enhance the tumoricidal effects of radiation. Many cancers are now treated 
with concomitant chemotherapy and radiation with absolute benefits in overall survival on 
the order of 5-10%, but at the cost of increased toxicity of treatment (Auperin et al. 2010; 
Green et al. 2001; Pignon et al. 2009). Advancements in disease targeting and release 
properties make nanoparticles an intriguing choice for combining these two therapies in vivo 
with the hope of reducing toxicity and enhancing efficacy, similar to what is seen with 
nanoparticle chemotherapy agents already on the market such as Doxil and Abraxane.  
Wang et al. described such a combined modality nanoparticle, ChemoRad NP (Wang et al. 
2010). Using a lipid-polymer hybrid nanoparticle platform, researchers synthesized a 
particle containing docetaxel chemotherapy within the core and used metal chelation with 
DMPE-DPTA to attach Yttrium-90, a beta-emitter that has been effectively used in the clinic 
when conjugated to anti-CD-20 monoclonal antibodies for treatment of Hodgkin’s 
lymphoma. Both agents were attached in therapeutic quantities with 5% docetaxel by 
weight in the NP and 100 μCi Y-90/mg NP. This activity of Yttrium is enough to deliver 6 
Gy of radiation to a tumor target based on pharmacokinetic studies of the NP.   The surface 
of the NP was conjugated via DSPE-PEG with the aptamer A10, a ligand that targets 
prostate specific membrane antigen (PSMA). In a preliminary study of the molecule, in vitro 
profiling showed the NP to have excellent stability and controlled release properties while 
successfully targeting tumor cells using the aptamer ligand.  Comparison of the combined 
modality NP to single-agent NP and non-targeted NP as controls showed that the 
ChemoRad NP has higher therapeutic efficacy than the control options. ChemoRad NP is 
believed to be the first targeted nanoparticle for delivery of chemoradiation therapy.  
Chow et al. report on a second combined modality particle combining Indium-111 and 
vinorelbine in a pegylated liposome carrier (Chow et al. 2008). This nanoparticle platform 
did not have a targeting ligand, but showed tumor selectively by the EPR effect on mice 
with colorectal carcinoma xenografts. The agent showed antitumor efficacy both when 
chemotherapy and radiation were included and when the single agents alone were used. 
Because Indium-111 produces both a gamma photon and auger electron, this suggests the 
auger electron may contribute meaningfully to tumor kill. Because of this decay feature, In-
111 has potential as a dual diagnostic and therapeutic (theranostic) agent.  
5. Summary 
Advances in nanotechnology have inspired the development of nanoparticles for medical 
applications. Radioisotopes have grown to be an integral part of this field both for purposes 
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of drug development and now diagnostic and therapeutic applications. The flexibility of 
NPs enables the utilization of radioisotopes in novel applications. The wide range of 
ongoing nanoparticle research and the explosion of interest in the field are both testaments 
to the versatility and potential of this expanding branch of science in which radioisotopes 
promise to continue playing an important role. 
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